Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non‐small‐cell lung cancer: A network meta‐analysis of nine eligible …
GF Liu, XF Li, SN Yu, YY Miao… - Journal of Cellular …, 2019 - Wiley Online Library
Recently, targeted agents were reported to improve overall survival, progression‐free
survival (PFS), response rate, and quality of life compared with cytotoxic chemotherapies …
survival (PFS), response rate, and quality of life compared with cytotoxic chemotherapies …
Drug induced hepatotoxicity in targeted therapy for lung cancer
C Xueqin, Y Shaoyu, MA Shenglin - Zhongguo Fei Ai Za Zhi, 2014 - search.proquest.com
中国肺癌杂志 www.lungca.org Page 1 ·685· 中国肺癌杂志2014年9月第17卷第9期 Chin J Lung
Cancer, September 2014, Vol.17, No.9 · 综述 · 肺癌靶向药物肝脏毒性作用研究进展 陈雪琴 杨邵 …
Cancer, September 2014, Vol.17, No.9 · 综述 · 肺癌靶向药物肝脏毒性作用研究进展 陈雪琴 杨邵 …
[PDF][PDF] Successful treatment of a patient with an EGFR-mutated pulmonary adenocarcinoma and a history of uremia with erlotinib after gefitinib-induced kidney …
L Zhou, Z Chen - International Journal of Radiation Research, 2021 - sid.ir
ABSTRACT A 48-year-old male patient with a history of uremia was diagnosed with
pulmonary adenocarcinoma based on a computed tomography (CT) scan and biopsy. In …
pulmonary adenocarcinoma based on a computed tomography (CT) scan and biopsy. In …
[PDF][PDF] In vivo/in vitro models for investigation of tyrosine kinase inhibitors induced dermal toxicities
金沢大学大学院医薬保健学総合研究科創薬科学専攻… - kanazawa-u.repo.nii.ac.jp
Tyrosine kinase inhibitors (TKIs) are anticancer drugs that enable individualized and
rationalized treatment based on target gene products. However, these drugs have a …
rationalized treatment based on target gene products. However, these drugs have a …
[PDF][PDF] Stomatitis and EGFR-tyrosine kinase inhibitors: a review of current literature in 4353 patients
C Arena, G Troiano, K Zhurakivska… - Clin. Oncol.(R. Coll …, 2018 - pdfs.semanticscholar.org
Conventional chemotherapy presents a wide range of side effects including oral toxicities
such as hyposalivation, dysphagia, discomfort, taste alterations and mucositis. Oral …
such as hyposalivation, dysphagia, discomfort, taste alterations and mucositis. Oral …
[HTML][HTML] Gefitinib–terapiya vybora 1-y linii nemelkokletochnogo raka legkogo u bol'nykh s nalichiem mutatsiy v gene EGFR
LV Bolotina - Journal of Modern Oncology, 2013 - edgccjournal.org
С позиций современных знаний о роли мутаций определенных генов и связанной с
этим эффективностью лекарственной терапии необходимо проведение генетических …
этим эффективностью лекарственной терапии необходимо проведение генетических …
PERBANDINGAN EFIKASI GEFITINIB DAN ERLOTINIB PADA PASIEN KANKER PARU JENIS KARSINOMA BUKAN SEL KECIL DI POLI ONKOLOGI SATU ATAP RS …
AA Laitupa - 2019 - repository.unair.ac.id
Latar Belakang Kanker paru sering terjadi setelah kanker payudara dan kanker prostat.
Gefitinib dan Erlotinib adalah dua EGFR TKI yang memiliki mekanisme yang sama dan …
Gefitinib dan Erlotinib adalah dua EGFR TKI yang memiliki mekanisme yang sama dan …
[PDF][PDF] Гефитиниб–терапия выбора 1-й линии немелкоклеточного рака легкого у больных с наличием мутаций в гене EGFR
ЛВ Болотина - Современная онкология, 2013 - omnidoctor.ru
Резюме С позиций современных знаний о роли мутаций определенных генов и
связанной с этим эффективностью лекарственной терапии необходимо проведение …
связанной с этим эффективностью лекарственной терапии необходимо проведение …
1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl) pyrimidin-2-yl)-1 h-pyrazol-4-ol and use thereof in the treatment of cancer
S Bilic, JAC Gomez, JS CAMERON, JCCP Laria… - 2018 - Google Patents
WO2018146612A1 - 1-(4-amino-5-bromo-6-(1 h-pyrazol-1-yl)pyrimidin-2-yl)-1 h-pyrazol-4-ol
and use thereof in the treatment of cancer - Google Patents WO2018146612A1 - 1-(4-amino-5-bromo-6-(1 …
and use thereof in the treatment of cancer - Google Patents WO2018146612A1 - 1-(4-amino-5-bromo-6-(1 …
In vitro-Untersuchungen zur Wirksamkeit von Erlotinib, Gefitinib und Cetuximab bei der Behandlung des Kopf-Hals-Karzinoms
NB Neckel - 2018 - opus.bibliothek.uni-wuerzburg.de
Das derzeit einzige für die Therapie des Kopf-Hals-Karzinoms zugelassene spezifische
Therapeutikum ist der monoklonale Antikörper Cetuximab, welcher eine gezielte Blockade …
Therapeutikum ist der monoklonale Antikörper Cetuximab, welcher eine gezielte Blockade …